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Abstract
HIV-1 entry requires the cell surface expression of CD4 and either the CCR5 or CXCR4 coreceptors on host cells. Individuals
homozygous for the ccr5D32 polymorphism do not express CCR5 and are protected from infection by CCR5-tropic (R5) virus
strains. As an approach to inactivating CCR5, we introduced CCR5-specific zinc-finger nucleases into human CD4+ T cells
prior to adoptive transfer, but the need to protect cells from virus strains that use CXCR4 (X4) in place of or in addition to
CCR5 (R5X4) remains. Here we describe engineering a pair of zinc finger nucleases that, when introduced into human T cells,
efficiently disrupt cxcr4 by cleavage and error-prone non-homologous DNA end-joining. The resulting cells proliferated
normally and were resistant to infection by X4-tropic HIV-1 strains. CXCR4 could also be inactivated in ccr5D32 CD4+ T cells,
and we show that such cells were resistant to all strains of HIV-1 tested. Loss of CXCR4 also provided protection from X4
HIV-1 in a humanized mouse model, though this protection was lost over time due to the emergence of R5-tropic viral
mutants. These data suggest that CXCR4-specific ZFNs may prove useful in establishing resistance to CXCR4-tropic HIV for
autologous transplant in HIV-infected individuals.
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Introduction
For HIV to infect cells, the viral envelope (Env) protein must
bind to the host protein CD4 and then to a coreceptor, most
commonly CCR5 (R5 HIV) (reviewed in [1]). The importance of
CCR5 for HIV-1 pathogenesis is shown by the fact that
individuals who are homozygous for an inactivating 32 base pair
deletion in ccr5 (ccr5D32) are highly resistant to HIV infection
[2,3], while heterozygotes typically live longer after HIV infection
due to reduced CCR5 expression levels [4,5]. Recently, an HIV
infected patient with acute myelogenous leukemia received a
bone marrow transplant from a ccr5D32 homozygous donor [6].
This patient’s viral load remains undetectable even in the absence
of anti-retroviral therapy more than three years post-transplant,
suggesting that this individual’s HIV infection has been
eradicated. In theory, the success of this approach could be
recapitulated by inhibiting CCR5 with an orally bioavailable
small molecule such as maraviroc, which binds to CCR5 and
prevents its use by most R5 HIV-1 strains. However, virus strains
that can utilize CXCR4 either in place of (X4 HIV) or in
addition to CCR5 (R5X4 HIV) are found at significant levels in
roughly 50% of late-stage infected individuals [7,8], supporting
the need for therapies targeted to CXCR4 [9]. Ideally, an
approach to target CXCR4 would complement CCR5-specific
therapy, but the broad expression pattern of CXCR4 has made
systemic inhibition of this coreceptor by small molecules
problematic [10,11]. In addition, resistance to CCR5 and
CXCR4 antagonists can arise in patients by mutations in the
viral envelope protein that enable it to utilize the drug-bound
forms of these coreceptors [12–16]. The ability of HIV-1 to adapt
to new selective pressures and the plasticity with which Env
interacts with its coreceptors argues for approaches that reduce or
eliminate coreceptor expression rather than simply altering
coreceptor conformation. If approaches could be developed that
specifically target expression of both CCR5 and CXCR4 on
CD4+ T cells, virus entry should be inhibited more effectively.
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CCR5 expression in human cells, including the use of ribozymes
[17,18], single-chain intracellular antibodies [19], trans-dominant
coreceptor mutants [20], and RNAi [21,22]. However, these studies
are limited by the requirement for stable expression of an exogenous
gene. To circumvent this, a CCR5 specific zinc-finger nuclease pair
(R5-ZFNs) has been developed [23]. Zinc finger proteins that
recognize a specific 24 bp DNA sequence are fused with a
monomeric cleavage domain from FokI endonuclease that functions
only as a dimer (Figure 1). For DNA cleavage to occur, two zinc
finger proteins must bind, each to specific, adjoining sequences in the
CCR5 gene, leading to FokI dimerization and subsequent DNA
cleavage resulting in a double strand break [24–26]. The double
strand break then can be repaired by error-prone non-homologous
end joining (NHEJ) often introducing insertions and deletions leading
to a non-functional gene product when this break is placed within the
coding region of the targeted gene [27]. Following introduction into
human CD4+ T cells [23] or hematopoietic stem cells [28] via an
adenovirus vector or DNA nucleofection, respectively, the ccr5 gene
was efficiently and specifically disrupted. This confers protection in
vitro and in humanized mice to infection by HIV-1 isolates that
require CCR5 (but not CXCR4). Several early stage clinical trials
using autologous infusions of ZFN-generated CCR5-modified CD4+
T cells are currently underway (clinicaltrials.gov identifiers
NCT00842634, NCT01252641, NCT01044654).
In this study we describe the design and pre-clinical evaluation of a
CXCR4-specific ZFN pair (X4-ZFNs) that specifically and efficiently
disrupts cxcr4, rendering human CD4+ T cells permanently resistant
to HIV-1 strains that require CXCR4 for infection. We also
demonstrate that cxcr4 can be safely and efficientlydisrupted in CD4+
T cells obtained from ccr5D32 homozygotes resulting in cells resistant
to all strains of HIV-1 tested. This suggests that combined treatment
of mature CD4+ T cells with X4-ZFNs and R5-ZFNs can provide
permanent protection against HIV-1 infection.
Methods
Zinc-finger nuclease constructs
We designed ZFNs specific to the human and rhesus CXCR4
and CCR5 genes using a previously described approach [29]. One
ZFN pair was used to target both the human and rhesus macaque
CXCR4 genes since the 24 bp target sequences are identical.
Zinc-finger proteins were optimized against the target gene
sequence and assembled as described [30] from an archive of in-
vitro-selected modules [31,32]. The ZFP moieties (target gene; ZFP
name; target sequence (59R39); recognition a-helices (finger
number)) are as follows: CXCR4; X4-ZFN-L; GTA-
GAAGCGGTC, DRSALSR (1), RSDDLTR (2), QSGNLAR
(3), QSGSLTR (4); CXCR4; X4-ZFN-R; GACTTGTGGGTG,
RSDSLLR (1), RSDHLTT (2), RSDSLSA (3), DRSNLTR (4).
Rhesus CCR5; rhR5-ZFN-L; GATGAGGACGAC, RSDNLAR
(1), TSGNLTR (2), RSDNLAR (3), TSGNLTR (4); Rhesus
CCR5; rhR5-ZFN-R; AAACTGCAAAAG; RSDNLSV (1),
QKINLQV (2), RSDVLSE (3), QRNHRTT (4)., The human
CCR5-specific ZFNs are described in Perez et al [23]. The Ad5/
F35 adenoviral vectors were generated on an E1/E3 deleted
backbone. The ZFNs targeting either the cxcr4 or ccr5 genes
were linked via a 2A peptide sequence and cloned into the
pAdEasy-1/F35 vector under control of the CMV TetO
promoter, and the Ad5/F35 virus for each construct was
generated using TREx 293T cells as described [33]. The Ad5/
F35 vector encoding the X4-ZFNs is identical to that use by
Nilsson, et al. [33] except for the ZFN inserts, promoter, polyA
and linker sequences.
Cel1 (surveyor nuclease) assay
Genomic DNA was extracted with the MasterPure kit (Epicentre
Biotechnologies) accordingto manufacturer’s instructions. Frequen-
cy of gene modification by NHEJ was evaluated as described
previously [23,25,28]. Briefly, the purified genomic DNA was used
as a template to amplify a fragment of the cxcr4 gene using the
specific primers (human CXCR4: 59-CAACCTCTACAG-
CAGTGTCCTCATC -39and 59- GGAGTGTGACAGCTTG-
GAGATG -39; rhesus CXCR4: 59- GGTGGTCTATGTTG-
GAGTCTGG -39and 59- GGAGTGTGACAGCTTGGAGATG
-39) in the presence of a
32P-dATP and dCTP. The PCR products
were then heated, allowed to re-anneal followed by treatment with
the mismatch-sensitive Surveyor nuclease as described in order to
detect insertions and deletions caused by NHEJ. For humanized
mice samples, whole genome amplification using the REPLI-g Mini
Kit(Qiagen) was conductedprior tothesurveyornucleaseassaydue
to limiting cell numbers.
Human CD4+ T cell stimulation and transduction
Fresh CD4+ T cells from normal human donors, purified by
negative selection, were obtained from the Center for AIDS
Research Human Immunology Core at the University of
Pennsylvania. 2.5 million CD4+ T cells were seeded at a density
of 0.8610
6 cells/ml in RPMI containing 10% fetal calf serum, 1%
penicillin/streptomycin, and 100 U/ml interleukin-2 (IL-2). The
cells were stimulated with anti-CD3/anti-CD28 coated magnetic
beads at a 3:1 bead to cell ratio [34]. Approximately 18 hrs post-
stimulation, the cells were transduced with an Ad5/F35 vector
encoding either the X4-ZFNs or R5-ZFNs at a multiplicity of
infection (MOI) of 600. Beginning 72 hours post-stimulation, cells
were counted every 48 hours using trypan blue dye exclusion on
an automated hemocytometer (Countess, Invitrogen) and split to
0.8610
6 with fresh media containing 100 U/ml IL-2. Five days
post-stimulation, the magnetic beads were removed and washed
twice in fresh media. Cells were counted and split until cell growth
plateaued 10–14 days post stimulation. For longer experiments,
cells were restimulated with beads and cultured for an additional
10–14 days.
Author Summary
For HIV to enter T cells, the virus first binds to a primary
surface receptor CD4 and then to a coreceptor, either CCR5 or
CXCR4. Previously we engineered zinc-finger nucleases
(ZFNs) to specifically disrupt the CCR5 gene in primary
human T cells, the predominant cell type infected and killed
by HIV. This makes the cell permanently resistant to CCR5-
tropic HIV; however, viruses that can utilize CXCR4 can still
infect cells. ZFNs function as molecular scissors that cut a
specific region of DNA. Then, the cell’s own machinery repairs
this cut, often introducing mutations that result in a non-
functional protein. Currently, a clinical trial is underway in
which HIV-infected individuals’ own cells are removed from
their blood, treated with the CCR5-ZFNs, and then infused
back. Here, we report the use of novel zinc-finger nucleases
that specifically and permanently disrupt the CXCR4 gene in T
cells. This treatment results in resistance to CXCR4-tropic HIV.
In addition, we combine CXCR4 and CCR5 genetic disruption
to make cells resistant to all strains of HIV. Our long-term goal
is to engineer HIV-resistant CD4+ T cells in infected
individuals that can be reinfused and hopefully enable them
to control infection in the absence of anti-viral drugs.
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Five days post-stimulation the anti-CD3/anti-CD28 coated
magnetic beads were removed from each of the three cultures
(non-transduced (NTD), AdX4-ZFNs, and AdR5-ZFNs) and 2.5
million cells were seeded in each of four cultures that were
subsequently infected with either Bk132 (primary X4 isolate),
HxB2 (lab-adapted X4 isolate), R3A (R5X4 primary isolate), or
media only (mock). 100 ng p24 of HIV-1 was used per million
cells.
Flow cytometry
All staining was done at room temperature in FACS Wash
Buffer (1 mM EDTA, 2.5% fetal calf serum in PBS) and all
antibodies were from BD Biosciences unless otherwise noted. 0.5–
1.0610
6 cells were washed in PBS and stained with Live/Dead
Aqua (Invitrogen) for 10 min. Then, anti-CD4 PE Cy5.5 and anti-
CXCR4 APC (clone 12G5) were added and cells were stained for
20–30 minutes. Cells were then washed and permeabilized per
manufacturer’s protocol using Cytofix/cytoperm (BD) and stained
intracellularly for HIV gag with KC57-RD1 (Beckman Coulter).
For compensation, ArC beads (Invitrogen) were used for live/
dead, and CompBeads (BD) were used for all other fluorochromes.
To detect wtCXCR4 and CXCR4D18 in 293T transient
transfection experiments, anti-CXCR4 APC (clone 12G5) and
anti-CXCR4 PE (clone 4G10) (Santa Cruz Biotechnologies) were
used. All samples were run on an LSRII (BD) and analyzed using
FlowJo 8.8.6 (Treestar Inc).
Events were gated as follows: singlets (FSC-A by FSC-H), live
cells (SSC-A by Live/Dead), lymphocytes (FSC-A by SSC-A),
CD3+CD4+ (CD3 by CD4), and then events were divided into
CXCR4+ and CXCR4- populations based upon a fluorescence
minus one (FMO) control.
Figure 1. Zinc finger nucleases (ZFNs) bind, cleave, and disrupt cxcr4. (A) A CXCR4-specific ZFN pair was generated, comprised of two DNA-
binding zinc finger proteins (ZFPs) each fused with a FokI endonuclease monomer. Each ZFP was designed to target 12 bp of cxcr4 sequence (in red),
separated by 6 bp (in blue), conferring 24 bp of total specificity. Upon binding of both ZFPs, the FokI domains can dimerize and cleave the double
stranded DNA. The subsequent double strand break is then repaired by error prone non-homologous end-joining resulting in various targeted
mutations and a non-functional protein product. (B) The most common mutations induced by the X4-ZFNs, as detected by 454 deep sequencing, are
indicated with their frequencies among all ZFN-induced lesions. In-frame deletions were preferentially generated with the most common being an
18 bp deletion, referred to as CXCR4D18. Frequences were averaged across five independent experiments in the absence of HIV infection.
doi:10.1371/journal.ppat.1002020.g001
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Genomic DNA was isolated from CD4+ T cells using the
QIAamp DNA Micro Kit (Qiagen). For each condition, 200 ng
genomic DNA was then PCR amplified using Platinum Taq High
Fidelity (Invitrogen) using the following primers plus 454 adaptor
sequences and 8 letter DNA barcodes: CAACCTCTACAG-
CAGTGTCCTCATC (forward) and GGAGTGTGACAGC-
TTGGAGATG (reverse). Cycle conditions were 95u for 5 min,
then 30 cycles of 95u for 30 sec, 55u for 3 sec, 68u for 30 sec,
followed by 68u for 2 min. Following PCR amplification the PCR
product was analyzed on a 2% agarose gel and then extracted and
gel purified using Wizard SV Gel and PCR Clean-Up System
(Promega). Quant-iT dsDNA High-Sensitivity Assay Kit (Invitro-
gen) was then used to determine the concentration of each bar-
coded amplicon. DNA samples were then pooled at an equimolar
ratio and run on a Roche/454 GS FLX using standard chemistries
at the University of Pennsylvania’s DNA Sequencing Facility.
Approximately 30,000–100,000 reads were obtained for each
experiment.CXCR4pyrosequencing data were assigned to samples
by DNA barcode. Any reads containing ambiguous base calls or
without a perfect match to barcode and primer were discarded. All
remaining reads were aligned to the CXCR4 reference sequence
using Mosaik (http://bioinformatics.bc.edu/marthlab/Mosaik). All
deviationsfrom the CXCR4consensussequence 40base pairsupor
downstream from the ZFN bindingsite were determined. Any reads
that did not extend across this region or that failed to align were
discarded. Reads containing only two or fewer substitutions were
not classified as mutations as these likely represent sequencing
artifacts. Next, background pyrosequencing error, identified by an
untransduced control sample, was subtracted from each group of
reads. For frameshift analysis, the sequencing error was determined
and subtracted for each individual insertion or deletion size.
To ensure sufficient sampling of diverse amplicons, at least
200 ng gDNA was used for CXCR4 analysis and at least 400 ng
gDNA was used for off-target site amplification, representing the
genomic DNA content of approximately 70,000 and 140,000
alleles, respectively. Determining genetic disruption frequency by
both the Cel1 and 454 assays require the assumption that wild type
and disrupted alleles are not differentially amplified.
Systemic evolution of ligands by exponential enrichment
(SELEX) and determination of off-target sites
To empirically determine the DNA binding preference of the
X4-ZFNs, we employed SELEX as previously described [23].
Briefly, each ZFP was HA-tagged and incubated with randomized
DNA oligonucleotides and anti-HA Fab fragments. Any DNA
bound to the ZFPs was then isolated and amplified. The newly
amplified DNA was then used to repeat this process for a total of
four rounds of enrichment. The DNA pool was then sequenced at
approximately 506 coverage to generate a positional-weighted
matrix. This matrix was then aligned to the human genome with
the following criteria: putative off-target sites could have up to six
mismatches compared to the SELEX consensus sequence, the ZFP
pairs must be separated by either 5 or 6 bps, and both ZFP homo-
and heterodimers were considered. Off-target sites were ranked
and scored by multiplying the probability of each nucleotide at
each of the 12 positions of the positional-weighted matrix. The
highest scores were then deemed most likely to be disrupted. 454
off-target site data was analyzed as discussed previously [23].
NSG mice
NSG (NOD.Cg-Prkdc
scidIl2rg
tm1Wjl/Szj) mice, 8–9 weeks old at
time of initial injection, were derived from breeders purchased
from The Jackson Laboratory (Bar Harbor, ME). Animals were
maintained in a defined flora animal barrier facility at the
University of Pennsylvania’s Stem Cell and Xenograft Core.
Human CD4+ T cells were isolated and stimulated as previously
described and then transduced with an Ad5/F35 vector expressing
either the R5-ZFNs or the X4-ZFNs at an MOI of 600. Cells were
maintained as previously described. Ten days post stimulation 10
7
modified cells resuspended in 100 mL PBS were injected
intravenously into the tail vein of each mouse. 23 animals received
cells treated with X4-ZFNs and 22 mice received cells treated with
R5-ZFNs. Animals were randomized by age, sex, and cage. Mice
were maintained on the antibiotic Baytril (Bayer) for 24 hours
post-injection.
To infect the mice with HIV-1, 10
5 autologous CD4+ T cells
previously infected with X4 HIV-1 strain Bk132 were injected into
the tail vein of each mouse. Autologous cells used to infect mice
that were not transduced were obtained and stimulated simulta-
neously as the initially engrafted cells. Five days post-stimulation
cells were infected with 100 ng p24/million cells and then were
cryopreserved four days post-infection. Cell engraftment was
assessed 27 days post injection, and mice were infected with HIV-1
the following day.
To obtain whole blood, mice were anesthetized with isoflurane
and a capillary tube was used to drain the retroorbital vein.
Human CD4+ T cell counts were determined by staining 50 mlo f
whole blood in Trucount tubes (BD) with anti-CD45 FITC
(Biolegend), anti-CD3 Qdot 655 (Invitrogen), anti-CD4 Alexa
Fluor 700, anti-CD8 Pacific Blue (Biolegend), and anti-CXCR4
PE-Cy5. Human CD4+ T cells were defined as
CD45+CD3+CD4+CD8-.
At the time of sacrifice, a cardiac puncture was performed to
obtain maximal blood volume and then the spleen was harvested.
Spleens were homogenized and erythrocytes were lysed with ACK
lysis buffer (Invitrogen) before cell purification. Human CD4+ T
cells were then isolated with the Human CD4 Positive Selection
Kit using the Robosep robotic cell separator (Stem Cell
Technologies).
Rhesus macaque CD4+ T cell modification
Whole blood from rhesus macaques (Macaca mulatta) housed at
the Tulane National Primate Research Center was used for CD4+
T cell isolation and ZFN treatment. Peripheral blood mononu-
clear cells were isolated by centrifugation with 96% Ficoll (BD),
followed by erythrocyte lysis with ACK lysis buffer. CD4+ T cells
were then isolated by negative selection with a non-human
primate CD4+ T cell selection kit (Miltenyi). Cells were then
stimulated with 1:4 anti-CD3 (clone FN-18)/anti-CD28 (clone
L293) M-450 tosylactivated beads (Invitrogen) at a ratio of 1 bead
per cell [35,36].
Approximately 18 hours post-transduction, cells were trans-
duced with an Ad5/F35 vector expressing either the X4-ZFNs or
rhesus specific R5-ZFNs. Cells were maintained in culture as
human CD4+ T cells. Surveyor nuclease assay was performed six-
ten days post transduction to assess disruption efficiency.
Ethics statement
Human CD4+ T cells were obtained after written informed
consent and approval by the University of Pennsylvania’s
institutional review board. All humanized mouse experiments
were approved by the University of Pennsylvania’s Institutional
Animal Care and Use Committee (Protocol 802436), and were
carried out in accordance with recommendations in the Guide for
the Care and Use of Laboratory Animals of the National Institutes
of Health. All rhesus macaque experiments were approved by the
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(Protocol P0085; Project 3520) The Tulane National Primate
Research Center (TNPRC) is an Association for Assessment and
Accreditation of Laboratory Animal Care accredited facility
(AAALAC #000594). The NIH Office of Laboratory Animal
Welfare assurance number for the TNPRC is A3071-01. All
clinical procedures, including administration of anesthesia and
analgesics, are carried out under the direction of a veterinarian.
Blood was collected while the animals were anesthetized with
Tiletamine-zolazepam with Burprenorphine given as an analgesic.
All possible measures are taken to minimize discomfort of all the
animals used in this study. The University of Pennsylvania and
Tulane comply with NIH policy on animal welfare, the Animal
Welfare Act, and all other applicable federal, state and local laws.
Results
Design and characterization of X4-ZFNs
To genetically disrupt the CXCR4 allele, we designed a pair of
zinc-finger proteins (ZFPs) targeting the region of the cxcr4 gene
that encodes residues Asp 187 to Val 196 in the second
extracellular loop (ECL2) of this seven-transmembrane domain
receptor using methods previously described [29–32] (Figure 1).
The ECL2 was chosen because this region is less well conserved
amongst the CXC family of chemokine receptors, which should
reduce the frequency with which other CXC receptors might be
targeted, and because ECL2 is important in supporting interac-
tions with the HIV-1 Env protein [37,38]. Two ZFPs were
designed to bind each of two 12 bp targets separated by 6 bp in
this region of CXCR4. Each ZFP was then fused to a modified
FokI cleavage domain, active preferentially as a dimer to reduce
nonspecific DNA cleavage, resulting in zinc-finger nucleases
(ZFNs) [25]. Upon binding of both X4-ZFNs, the FokI nuclease
cleavage domains dimerize and then generate a double strand
break that can subsequently be repaired by error-prone NHEJ
resulting in mutations targeted to the cleavage site that can include
missense mutations, deletions and insertions (Figure 1).
Efficiency of CXCR4 allele disruption in human CD4+ T
cells
To determine the efficiency and specificity with which the cxcr4
genes could be disrupted in human T cells, we produced a
bicistronic Ad5/F35 vector to deliver the X4-ZFNs (AdX4-ZFNs).
The Ad5/F35 vector is a serotype 5 virus with the fiber protein
from a serotype 35 adenovirus that utilizes CD46 for entry as
opposed to the coxsackie and adenovirus receptor (CAR), which is
poorly expressed on human CD4+ T cells [39]. Primary human
CD4+ T cells were stimulated with anti-CD3/anti-CD28 coated
magnetic beads and transduced 18 hours later with AdX4-ZFNs,
AdR5-ZFNs which expresses previously described CCR5-specific
ZFNs [23], or an Ad5/F35 vector that expresses green fluorescent
protein (AdGFP). To identify optimal disruption conditions,
multiplicities of infection ranging from 100 to 1000 were
employed. Cell growth was monitored every 48 hours post-
stimulation for approximately two weeks and the efficiency of
CXCR4 disruption was assessed at day five post-transduction by
both the Surveyor nuclease assay and by deep-sequencing of the
CXCR4 target site. As shown in Figure 2A, the Ad5/F35 vectors
had a slight dose-dependent impact on cell growth at higher
multiplicities of infection that was similar with the AdX4-ZFNs
and AdGFP vectors.
Cxcr4 allelic disruption efficiencies as determined by either deep
sequencing or the Surveyor nuclease assay were comparable, and
were approximately 10% at an MOI of 100, 20% at an MOI of
300, 34% at an MOI of 600, and 38% at an MOI of 1000
(Figure 2B). For subsequent experiments we used an MOI of 600
as this provided near-maximal disruption efficiency with limited
impact on cell growth. Notably, this is also the MOI being used in
an adoptive therapy phase I clinical trial with R5-ZFNs.
Importantly, the level of cxcr4 disruption in cells from multiple
donors was stable over nearly four weeks in culture (Table S1),
indicating that CXCR4-disrupted cells continued to grow
normally. Cell proliferation remained dependent on stimulation,
and transformation has not been observed after treatment with
ZFNs (data not shown).
Mutations introduced by cleavage with X4-ZFNs
Deep sequencing of the ZFNs target site 10 days after
transduction made it possible to assess the mutations introduced
by NHEJ reactions following cleavage with X4-ZFNs. Of the
nearly 50,000 modified cxcr4 alleles analyzed across five indepen-
dent experiments, 81.1% (range 75.3–81.7%) contained pure
deletions from 1–64 bp in size with the most common deletions
being 2, 9, 12, 15, 18, and 25 bp, while 13.5% (range 12.8–16.9%)
of cxcr4 alleles contained pure insertions ranging from 1 to 69 bp
with more than 90% being 7 bp or less (Figure 1B). The remaining
5.3% (range 4.3–7.4%) of disruption events contained multiple
insertions and deletions that may be due to more extensive DNA
end-processing or multiple cycles of ZFN-mediated cleavage and
subsequent NHEJ. Surprisingly, frameshift mutations occurred at
a ratio of 0.90 in-frame per out-of-frame mutation as opposed to
the expected frequency of 0.50 (1 in-frame per 2 out-of-frame
mutations; Table S1). This unexpected bias likely resulted from
microhomology-mediated joining that produced in-frame dele-
tions. To our knowledge, preferential in-frame repair has not been
reported or seen with other ZFNs [23,40,41].
To further characterize the consequences of disruption
mediated by X4-ZFNs, we analyzed an unusually common lesion,
an in-frame 18 bp deletion (CXCR4D18) that results in the
deletion of DNA encoding amino acids R188 to D193 (Figure 1B).
This deletion comprised 11.2% (range 9.8 and 11.9%) of all cxcr4
disruptions across five independent experiments with cells from
five different donors. The resulting CXCR4D18 protein, contain-
ing a six-residue deletion in ECL2, could potentially be expressed
at the cell surface and support HIV infection. To examine this, we
transiently expressed CXCR4D18 or wt CXCR4 as a control in
293T cells, which have low endogenous CXCR4 expression.
CXCR4 cell surface and intracellular expression was detected by
flow cytometry after co-staining with the N-terminal specific
CXCR4 antibody 4G10 and the extracellular loop (ECL) specific
antibody 12G5 whose epitope includes the CXCR4D18 deleted
residues [42]. As expected, CXCR4 could be detected on the
surface of control cells by both the N-terminal and ECL
antibodies. However, CXCR4D18 was not detected at the cell
surface, though it was detected intracellularly by the N-terminal
antibody (Figure 3). In addition, cells expressing CXCR4D18
along with CD4 did not support HIV-1 infection. These findings
indicate that CXCR4D18, the most common in-frame deletion
resulting from the X4-ZFNs, does not readily traffic to the cell
surface and does not function as an HIV-1 coreceptor.
Specificity of cleavage by X4-ZFNs
Potential off-target genome modification comprises the pre-
dominant safety concern with ZFNs. Although ultra-deep full
genome sequencing could best identify off-target effects, it is
impractical and cost-prohibitive with current technology. Instead,
we took a more targeted approach that used an experimentally
derived binding site for each X4-ZFP to guide the identification of
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or SELEX (systemic evolution of ligands by exponential
enrichment) to determine the actual binding site preference of
each X4-ZFP (Figure S1) [43,44]. A positional-weighted matrix
was then generated of the 12 bp binding site and 1 bp flanking
region for each ZFP. A BLAST search against the human genome
was then used to determine the top 15 off-target binding sites by
allowing up to six mismatches per ZFP binding site, a 5 or 6 bp
gap between ZFPs, and formation of hetero or homodimers (Table
S2) [23]. To assess low frequency disruption events, we conducted
454 deep sequencing on all 15 sites in both control CD4+ T cells
and those treated with X4-ZFNs, yielding approximately 7,500–
26,000 reads per site in the ZFN-treated samples (Table S2). In a
sample with 26.9% of CXCR4 alleles disrupted, NHEJ events
Figure 2. X4-ZFNs mediated disruption of cxcr4 in primary human CD4+ T cells. (A) Primary human CD4+ T cells were stimulated and
transduced with an Ad5/F35 vector expressing either the X4-ZFNs (top) or GFP (bottom) at MOIs from 100–1000. Total live cells were counted at
different times after stimulation, and compared to an untransduced control. Data is from one of two independent experiments. (B) Cxcr4 disruption
was determined four and eight days post treatment with the X4-ZFNs by the surveyor nuclease assay (cel1).
doi:10.1371/journal.ppat.1002020.g002
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extragenic region on chromosome 12 and 0.8% (84/10531) in
ADAMTS17, a metalloprotease of unknown function [45]. The
four mutations out of 20,312 reads found in DEC1 (a putative
tumor suppressor [46]) and the single mutation out of 21,139 reads
found in an extragenic region of chromosome 11 could be due to
PCR and sequencing errors or to very low levels (,0.02%) of
ZFN-mediated cleavage events. Overall, the X4-ZFNs are highly
specific for cxcr4 with low frequency disruption clearly seen at 2 of
15 putative off-target sites with the highest homology to the
intended target.
X4-ZFNs confer in vitro protection to human CD4+ T cells
from HIV challenge
Disruption of both cxcr4 alleles should render human CD4+ T
cells resistant to X4- and perhaps some R5X4- viruses as well,
while cells harboring a single disrupted allele might express lower
levels of CXCR4 and so be more resistant to virus entry. To
determine whether ZFN-mediated disruption of cxcr4 indeed
protects CD4+ T cells from an in vitro HIV challenge, human
CD4+ T cells from three different ccr5 wild type donors were
stimulated and transduced with AdX4-ZFNs or an AdR5-ZFNs
control. Four days post-transduction, the cells were infected with
three diverse HIV-1 strains: BK132 (primary X4 HIV), HxB2
(lab-adapted X4 HIV), or R3A (primary R5X4 HIV). Approxi-
mately two weeks post-transduction the cells were restimulated
with anti-CD3/anti-CD28 beads, and cultures were maintained
for an additional two weeks.
In the absence of HIV infection, there was no detectable growth
difference between the X4-ZFNs treated, R5-ZFNs treated, and
non-transduced controls over the course of the experiment.
However, upon infection with the X4- or R5X4- HIV-1 strains,
X4-ZFNs treated cells maintained exponential growth compared
to profound cell death seen in the R5-ZFNs and untransduced
controls. Despite the ability of R3A to utilize both CCR5 and
CXCR4 to infect cell lines, in human CD4+ T cells stimulated
with anti-CD3/anti-CD28 coated magnetic beads, CCR5 is
downregulated causing transient resistance to R5 HIV [47]. Thus,
R5X4 HIV strains are likely to function predominantly as X4 HIV
strains under these conditions [47]. The growth advantage
conferred by treatment with X4-ZFNs in the presence of HIV
was magnified upon restimulation. (Figure 4A). This likely resulted
Figure 3. X4-ZFNs preferentially generate in-frame deletions resulting in the absence of CXCR4 cell surface expression. The most
common lesion induced by the X4-ZFNs was an 18 bp deletion, cxcr4D18, that results in deletion of the amino acid sequence RFYPND from the
second extracellular loop of CXCR4 (see Figure 1B). To determine if CXCR4D18 was expressed on the cell surface, a mock, wild type cxcr4,o rcxcr4D18
plasmid was transiently transfected into 293T cells that have low endogenous CXCR4 expression. Cells were then analyzed by flow cytometry after
being stained simultaneously with anti-CXCR4 clone 4G10, which recognizes the N-terminus, and clone 12G5 whose epitope includes the second
extracellular loop that is disrupted by the X4-ZFNs. WtCXCR4 was detected equally by both antibodies on the cell surface (middle panel, top row) and
intracellularly (middle panel, lower row). However, CXCR4D18 was not detected by the N-terminal antibody on the cell surface (right panel, top row),
but was detected when cells were permeabilized (right panel, bottom row) suggesting the 18 bp deletion prevents its expression on the cell surface.
doi:10.1371/journal.ppat.1002020.g003
Engineering Resistance to CXCR4-tropic HIV
PLoS Pathogens | www.plospathogens.org 7 April 2011 | Volume 7 | Issue 4 | e1002020Engineering Resistance to CXCR4-tropic HIV
PLoS Pathogens | www.plospathogens.org 8 April 2011 | Volume 7 | Issue 4 | e1002020from increased cell activation, which increases the ability of HIV
to infect and replicate in CXCR4 positive cells.
To determine whether the growth advantage conferred by X4-
ZFNs treatment in the presence of X4- and R5X4- HIV resulted
from a survival advantage of CXCR4 disrupted cells, we
performed flow cytometry at various time points post infection
as well as deep sequencing of the X4-ZFNs target site on HIV-
infected and uninfected cultures. In the absence of HIV infection,
the cxcr4 disruption frequency remained stable over time in four
independent experiments testing four different ccr5 wild type
donors as measured by deep sequencing. A representative
experiment is shown in Figure 4B and CXCR4 disruption data
from all experiments is shown in Tables S1 and S3. While CXCR4
gene disruption remained stable over time at approximately 30%,
CXCR4 gene disruption in HIV-infected cultures increased to
87%, 91%, and 88% in the presence of BK132, HxB2, and R3A
respectively after 21 days of infection. FACS analysis showed that
at day 19 post-HIV challenge, the frequency of CXCR4 negative
cells amongst all live mock HIV-infected CD4+ lymphocytes was
13.0% in untransduced cells, 14.1% in cells transduced with R5-
ZFNs, and 35.0% in cells transduced with X4-ZFNs compared to
greater than 98%, 97%, and 99% of Bk132, HxB2, and R3A
infected cultures transduced with the X4-ZFNs, (Figure 4C). We
also found that after 19 days post-HIV infection, reduced but
significant cell growth was detectable in several of the HIV-
infected control cultures, untransduced and treated with R5-ZFNs.
However, greater than 95% of these cells, compared to
approximately 10% of cells treated with X4-ZFNs, were
CD3+CD4- suggesting that the surviving cell population was
protected from HIV infection by down-regulating CD4 (Figure
S2). Thus, CXCR4 disruption had no impact on cell viability, but
conferred a significant survival advantage in the presence of HIV
strains that can use CXCR4 to infect cells. Furthermore, in control
cultures that were untransduced or treated with R5-ZFNs, viral
titers exponentially increased until extensive cell death began
approximately 8–10 days post infection. In contrast, in cultures
treated with X4-ZFNs viral titers steadily decreased after peak
viremia while cell growth remained exponential suggesting there
was not significant viral production (data not shown).
Ccr5D32 CD4+ T cells treated with X4-ZFNs are resistant
to R5 and X4 HIV
Given the ongoing adoptive therapy trial of CD4+ T cells
treated with R5-ZFNs and the anti-viral success of the recent
ccr5D32 bone marrow transplant in an HIV-infected patient [6],
we sought to determine if cxcr4 could be genetically disrupted
simultaneously with ccr5. Human CD4+ T cells from a ccr5D32
homozygote were transduced with AdX4-ZFNs or AdR5-ZFNs
and subsequently infected with HIV-1 strains Bk132, HxB2, and
R3A as described above. Representative data from one of two
independent experiments conducted in cells from the same donor
is shown in Figure 5 and data from both experiments is shown in
Tables S1 and S3. As seen in ccr5 wild type CD4+ T cells,
exponential cell growth was preserved in cultures treated with X4-
ZFNs compared to control cultures that were untransduced or
treated with R5-ZFNs (Figure 5A). In addition, disruption
frequency in cultures treated with X4-ZFNs as determined by
deep sequencing remained remarkably stable between 32–33%
from day 5 to day 26 post-transduction in the absence of HIV,
which suggests that simultaneous disruption of ccr5 and cxcr4 does
not adversely affect cell growth. However, in the presence of
Bk132, HxB2, and R3A, cxcr4 disruption increased after 21 days of
HIV challenge to 89%, 83%, and 90%, respectively (Figure 5B),
and was associated with markedly diminished virus replication
(data not shown), again consistent with significant protection
conferred by cxcr4 disruption. Thus, treatment with X4-ZFNs of
both wild-type and ccr5D32 CD4+ T cells confers stable cxcr4
disruption and a marked survival advantage in the presence of
R5X4-HIV and X4-HIV in vitro without any detectable effect on
cell growth or viability in the absence of HIV. This suggests that
both ccr5 and cxcr4 can be genetically targeted simultaneously for
the treatment of HIV infection, while preserving the replicative
capacity of the CD4+ T cells.
X4-ZFNs confer partial protection in NSG humanized
mouse model
As a first step in evaluating the safety and efficacy of the X4-
ZFNs in vivo, we employed a NSG humanized mouse model.
Briefly, human CD4+ T cells were stimulated with anti-CD3/anti-
CD28 beads and transduced with either AdX4-ZFNs or an AdR5-
ZFNs control at an MOI of 600. Cells were then expanded in vitro
for ten days after which 10
7 CD4+ T cells treated with X4-ZFNs
(n=23) or R5-ZFNs (n=22) were injected intravenously into each
mouse. Engraftment was assessed by peripheral blood CD4+ T
cell counts 27 days post-injection. All 45 animals successfully
engrafted; however, one animal that received cells treated with the
X4-ZFNs had a significantly higher but stable CD4+ T cell count
and was thus excluded as an outlier from the remainder of the
study. On day 28 post-engraftment, mice were intravenously
injected with 10
5 autologous CD4+ T cells that were previously
infected with the highly cytopathic X4 HIV-1 strain Bk132 or a
mock control. CD4 counts, viral load, and CXCR4 disruption
were then monitored to determine the effect of treatment with X4-
ZFNs.
To determine if X4-ZFNs impacted cell growth or viability in
the absence of HIV, we first compared CD4 counts over time
between the uninfected X4-ZFN and R5-ZFN control mice.
There was no significant difference in CD4 counts between the
two groups over the course of the 61 day experiment as
determined by a generalized estimating equation (GEE) method
(p=.88) (Figure 6A). Next, we examined the frequency of CXCR4
DNA disruption over time with the surveyor nuclease assay. At the
time of injection the percentage of cxcr4 alleles disrupted was
24.3%. This remained constant in both the blood (p=.32) and
spleen (p=.70) over the course of the experiment suggesting that
CXCR4 disruption did not significantly impact trafficking
between these two compartments (Figure 6B). Next, we charac-
terized CXCR4 cell surface expression over time by FACS. In the
R5-ZFN control group, with intact cxcr4 genes, 88% of CD4+ T
cells expressed CXCR4 protein at day 27 post engraftment,
Figure 4. Treatment of human CD4+ T cells with X4-ZFNs confers protection to HIV-1 challenge in vitro. (A) Human CD4+ T cells were
treated with the X4-ZFNs or R5-ZFNs expressed by Ad5/F35 vectors or were non-transduced (NTD). Four days later cells were infected with a primary X4
HIV-1 (Bk132), lab-adapted X4 HIV-1 (HxB2), primary R5X4 HIV-1 (R3A) or mock infected. The number of viable cells were measured at various times after
stimulation. Cells were re-stimulated on day 13 (arrows). (B) The proportion of disrupted cxcr4 alleles was determined at the indicated times post-
stimulation by 454 deep sequencing. The frequency of cxcr4 disruption was relatively constant in the mock-treated cells, but increased dramatically in
thepresenceofHIV-1.(C) FACS analysisusing aCXCR4-specificmonoclonalantibody was performedat19days postinfection(24 dayspost-stimulation).
Mock HIV-infected cultures are shown on the left and HIV infected cultures on the right. Data shown is one of three independent experiments.
doi:10.1371/journal.ppat.1002020.g004
Engineering Resistance to CXCR4-tropic HIV
PLoS Pathogens | www.plospathogens.org 9 April 2011 | Volume 7 | Issue 4 | e1002020Figure 5. Treatment with X4-ZFNs is effective in ccr5D32 homozgyous human CD4+ T cells. (A) Ccr5D32 CD4+ T cells were stimulated on
day 0 and transduced on day 1 with an Ad5/F35 vector expressing the X4-ZFNs, R5-ZFNs, or an untransduced control. On day 5, cells were HIV-
infected with a mock, primary X4 HIV-1 (Bk132), lab-adapted X4 HIV-1 (HxB2), or a primary R5X4 HIV-1 (R3A). Live cells were counted approximately
every two days. Cells were restimulated on day 13 (arrows). (B) Cxcr4 disruption frequency was assessed at various times by 454 deep sequencing.
Disruption remained stable in the absence of HIV-1 infection, but profoundly increased in the presence of the three HIV-1 strains examined. Data
shown is from one of two representative experiments.
doi:10.1371/journal.ppat.1002020.g005
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disruption) as determined by a fluorescence minus-one (FMO)
control. This difference persisted over time in the absence of HIV-
1 infection (p ,0.001) (data not shown). Together the stable
disruption of CXCR4 as determined by both the surveyor
nuclease assay and flow cytometry suggests that CXCR4
disruption did not negatively impact cell viability or growth in
humanized NSG mice over a two-month period. As expected,
xenogeneic graft versus host disease (GVHD), assessed clinically by
dermatitis and hair loss, was observed in mice receiving cells
treated with both R5-ZFNs and X4-ZFNs in the absence of HIV
challenge. The development of GVHD was equivalent between
the two groups (data not shown), suggesting that treatment with
X4-ZFNs did not affect CD4+ T cell effector functionality.
In response to X4 HIV challenge with HIV-1 Bk132, CD4
counts decreased in both X4-ZFN and R5-ZFN mice. However,
Figure 6. Treatment with X4-ZFNs confers partial protection to HIV-1 in humanized mice in vivo. NSG mice were injected with human
CD4+ T cells treated with X4-ZFNs or R5-ZFNs. 28 days post injection, mice were infected with primary X4 HIV-1 (Bk132) or were mock-infected. (A)
CD4+ T cell counts were measured every 7–10 days post infection. In the presence of Bk132, treatment with X4-ZFNs conferred protection at 14 d.p.i
(p=.05); however, this protection wanes by 34 d.p.i. (p=.88) (B) Cxcr4 disruption frequency was assessed by the surveyor nuclease assay in both
peripheral blood (p,.001) and spleen (p,.001). At day 34 post infection, human CD4+ T cells were purified by positive selection prior to analysis to
reduce any bias from low frequency contaminating human cells. Only samples with a detectable PCR signal are shown. Disruption frequency did not
deviate significantly from the cell innoculum in either the blood or spleen. Data in (A) and (B) were analyzed by a general estimating equation (GEE).
(C) HIV-1 Env from X4-ZFN mouse plasma was sequenced revealing a consensus Y302N mutation. To evaluate coreceptor tropism, a representative
Env from the X4-ZFN mice and the viral innoculum were pseudotyped and used to infect NP2 cell lines expressing CD4 and either CCR5 or CXCR4. R5
HIV-1 (JRFL), R5X4 HIV-1 (R3A), and X4 HIV-1 (TYBE) controls are shown. Infectivity on NP2/CD4/CXCR4 cells was divided by that on NP2/CD4/CCR5
cells to determine relative coreceptor use. Data is an average of three independent experiments each done in triplicate. Error bars represent standard
error.
doi:10.1371/journal.ppat.1002020.g006
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group exhibited a mean 1.1 log CD4 count protection by day 14
post infection (p=.05 for a parametric t-test). However, this
protective effect waned over time and there was no significant
difference in CD4 counts by day 33 post infection (p=.88)
suggesting that treatment with X4-ZFNs conferred only transient
protection (Figure 6A).
One mechanism that could account for this would be if
mutations arose in the viral Env protein to enable it to use
CCR5. To explore this possibility, we bulk cloned and
sequenced the V3 loop of Env, the main determinant of
coreceptor tropism [48], from plasma isolated from three R5-
ZFN mice and three X4-ZFN mice at the time of sacrifice. We
identified a single amino acid substitution (Y302N) present in
Env isolated from X4-ZFN mice but not R5-ZFN mice or the
viral innoculum. Next, we cloned six distinct, functional Envs
from the X4-ZFN mice and three distinct, functional Envs from
the viral innoculum. As full length Bk132 Env would not
pseudotype on an NL43 HIV core we truncated the cytoplasmic
tail of the Envs [49,50], and conducted tropism testing on NP2
cell lines expressing CD4 with either CCR5 or CXCR4. Of the
six functional Envs from X4-ZFN mice, four contained the
Y302N mutation. Interestingly, these four Envs were able to
utilize CCR5 and CXCR4 equivalently, similar to the R5X4-
tropic control R3A. All clones with the wild type Tyr302,
including the Envs from the viral innoculum and two Envs from
X4-ZFN mice utilized CXCR4 approximately 1000-fold more
efficiently than CCR5 and comparably to the X4-tropic control
TYBE (Figure 6C). Thus, in an NSG humanized mouse model
of HIV infection, the cells treated with X4-ZFNs engrafted,
trafficked, and persisted comparably to control cells. In addition,
treatment with X4-ZFNs resulted in significant transient
protection of CD4+ T cell counts in response to X4-tropic
HIV challenge, and HIV challenge provided cxcr4 disrupted cells
with a survival advantage as determined by increase of cxcr4
disruption in the presence but not the absence of HIV. However,
the extent of the protection conferred by the X4-ZFNs was
mitigated by evolution or outgrowth of preexisting R5X4-tropic
HIV.
ZFN-mediated coreceptor disruption is feasible in rhesus
macaque CD4+ T cells
While humanized mouse models for HIV infection have utility,
the model is limited due to incomplete immune reconstitution,
development of xenogeneic graft versus host disease (GVHD), and
the absence of normal T cell homeostasis. For these reasons and
others, the NSG model is suboptimal compared to non-human
primate models to further elucidate the safety and efficacy of
treatment with X4-ZFNs and R5-ZFNs. As a proof of concept for
future clinical adoptive therapy studies, we attempted to disrupt
the ccr5 and cxcr4 genes with ZFNs in rhesus macaque CD4+ T
cells. Briefly, rhesus CD4+ T cells were isolated from whole blood,
purified by magnetic bead negative selection, and then stimulated
with anti-CD3/anti-CD28 coated beads as previously described
[35,36]. As the 24 bp X4-ZFPs’ binding site is identical between
rhesus and humans, we were able to utilize the same ZFN pair.
However, in order to target rhesus CCR5, rhesus specific R5-
ZFNs were developed. As for human cells, the ZFNs were
delivered with an Ad5/F35 vector and disruption was assessed by
the surveyor nuclease assay. Utilizing a range of MOIs of 600,
1000, and 2000 we observed mean ccr5 and cxcr4 disruption levels
of 19.6% and 14.0%, respectively (Figure 7), which suggests that
adoptive therapy of cells modified with ZFNs is feasible to model
in rhesus macaques.
Discussion
The apparent eradication of HIV resulting from a ccr5D32
homozygous allogeneic bone marrow transplant into an HIV-
infected patient represents the first reported ‘‘cure’’ of HIV [6].
While an important proof-of-principle, few individuals could
benefit from allogeneic ccr5D32 homozygous transplants due to
toxicities of allogeneic rejection and limitations of finding sufficient
HLA-matched ccr5D32 homozygous donors. However, corecep-
tor-specific ZFNs represent a novel therapeutic approach to
recapitulate this success via autologous transplantation of gene-
modified hematopoietic stem cells and mature CD4+ T cells. Ccr5
can be efficiently disrupted in both human CD4+ T cells and
hematopoietic stem cells, conferring protection to HIV challenge
in vitro and in humanized mice [23,28]. In addition, transgenic
autologous hematopoietic stem cells can be successfully trans-
planted in HIV-infected individuals [18] and several phase I
adoptive transfer trials of CD4+ T cells treated with R5-ZFNs in
HIV infected individuals are currently underway. By design, this
strategy addresses only viruses that require CCR5 to infect cells.
Our long-term goal, therefore, is to explore the potential to
genetically disrupt both ccr5 and cxcr4 for cell replacement
therapies in HIV infected individuals, and in the case of cxcr4 do
so in a way that specifically targets CXCR4 on T cells and not the
many other cell types on which it is expressed.
Unlike for ccr5, there are no known humans with loss of function
cxcr4 mutations that would provide insight into the safety and
viability of cxcr4 disruption in mature CD4+ T cells. A concern
associated with targeting CXCR4 is that it is broadly expressed,
while CCR5 expression is largely limited to hematopoietic cells.
CXCR4, along with its natural ligand CXCL12, plays a critical
role in normal B cell, cardiovascular, and cerebellar development,
though T lymphocytes appear to develop normally in cxcr42/2
mice [51]. Thus, it is possible that the selective disruption of cxcr4
in mature post-thymic CD4+ T cells may be tolerable. In addition
to its role in development, the CXCR4-CXCL12 axis is a potent
CD4+ T cell chemoattractant, and the broad expression of both
Figure 7. ZFNs can efficiently disrupt ccr5 and cxcr4 in rhesus
macaque CD4+ T cells. The X4-ZFN pair’s 24 bp binding site is
conserved between humans and rhesus macaques. However, the
human and rhesus R5-ZFNs have different binding sites; thus, a novel
CCR5-ZFN pair was generated targeting rhesus ccr5. The rhesus R5-ZFNs
and X4-ZFNs were delivered by Ad5/F35 vector at MOIs from 600–2000
into rhesus CD4+ T cells. Disruption frequency was measured by the
surveyor nuclease assay. Data shown is an average of three
independent experiments in cells from two different animals. Error
bars represent standard error.
doi:10.1371/journal.ppat.1002020.g007
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basal chemotaxis as opposed to a response to inflammation [52].
Indeed, inhibiting CXCR4 function systemically with the small
molecule antagonist plerixafor results in the peripheral mobiliza-
tion of hematopoetic stem cells, thus mitigating the potential of
such therapy for long-term anti-retroviral therapy. However,
plerixafor, which has not been reported to have adverse
immunologic consequences resulting from inhibiting CXCR4
function in mature CD4+ T cells, provides proof of principle that
inhibiting CXCR4 in mature CD4+ T cells may prove to be safe
and viable [10,53]. This suggests that this essential gene can be
targeted in a cell-type specific manner with CXCR4-specific ZFNs
that limits the toxicities of systemic disruption. While we have
demonstrated that CXCR4 is not essential for CD4+ T cell
viability and function in vitro and in humanized mice in vivo, the
redundancy of lymphocyte chemokine receptors and their ligands
makes predicting the in vivo consequences of cxcr4 disruption in a
normal host on CD4+ T cell function and trafficking difficult. We
conclude that a logical next step will be to study the consequences
of cxcr4 disruption in a non-human primate model of HIV
infection, which will simultaneously permit the assessment of the
consequences of this approach on T cell function and trafficking.
A significant advantage of ZFN gene modification, compared to
retrovirus based approaches, is that only transient transgene
expression is required to permanently engineer an HIV resistant
cell. As a result, adenovirus or other delivery mechanisms such as
RNA transfection can be employed that avoid toxicities that can
be associated with retroviral integration, such as cellular expansion
or transformation. This ‘‘hit-and-run’’ approach limits the
requirement of chronic transgene expression and the potential
leakiness of other approaches including siRNA [21,22], intrabo-
dies [19], and ribozymes [17]. However, like most gene transfer
approaches a major concern with ZFN technology is the potential
for oncogenesis due to off-target effects. While additional study is
clearly needed, our current studies have clearly identified off-target
disruption in two of the top 15 putative off-target sites: an
extragenic site on chromosome 12 and in the metalloprotease
ADAMTS17, which is not expressed in CD4+ T cells. In addition,
mature CD4+ T cells appear to be resistant to malignant
transformation [54], thus mitigating the potential concerns of
off-target disruption. Consistent with this, more than 200 people
have safely undergone adoptive transfer of genetically engineered
lymphocytes with no reported cases of therapy-induced oncogen-
esis [55]. Reasons for resistance to transformation of mature
lymphocytes are unclear, but may involve an unknown mechanism
that ensures the diversity of the TCR repertoire and thus limits
clonal outgrowth [54]. In contrast, the safety record of
hematopoietic stem cell gene therapy is less clear, with a significant
frequency of gene-therapy induced oncogenesis or clonal out-
growth reported in several hematopoietic stem cell trials [56,57].
One unexpected finding reported here is the predominance of
in-frame mutations, particularly in-frame deletions, resulting from
ZFN mediated cleavage of cxcr4. This has not been observed in
other ZFN studies reported thus far. The deep-sequencing
approach we have taken makes it possible to comprehensively
and accurately assess the types and frequencies of mutations that
result from ZFN cleavage followed by DNA repair. The striking
preponderance of in-frame deletions may have resulted from
toxicities of frameshift mutations shortly after treatment with X4-
ZFNs leading to decreased survival relative to in-frame mutants.
However, this is unlikely given that the frequency of in-frame
mutations remained stable over nearly four weeks in culture, that
there was no significant increase in cell death between control
cultures and those treated with X4-ZFNs, and that the most
common in-frame mutant was not expressed on the cell surface
and thus cannot maintain functionality. Rather, the preference for
in-frame deletions is likely due to preferential in-frame DNA
repair. The deletion in the most common X4-ZFN-induced lesion,
cxcr4D18, is flanked by a GTCA microhomology domain at the 59
and 39 ends consistent with a repair mechanism of microhomol-
ogy-mediated NHEJ [58]. Similar microhomology sites are present
in other common ZFN-induced cxcr4 mutants that we identified.
Thus, it appears that the nucleotide sequence of the X4-ZFN
binding site directs a preference for an in-frame repair mechanism.
Our studies provide a fundamental demonstration that
inactivation of cxcr4 by treatment with X4-ZFNs rendered human
CD4+ T cells resistant to infection by X4 virus strains, while
CXCR4 inactivation in the context of a ccr5D32 homozygous
background rendered cells resistant to infection by both R5 and
R5X4 strains. Genetic ablation of both CCR5 and CXCR4 will
likely make CD4+ T cells entirely resistant to HIV-1. Dual-
disruption of CCR5 and CXCR4 will be needed for maximal
therapeutic benefit since 46% of treatment-experienced individ-
uals harbor R5X4 strains of HIV compared to 4% with only X4-
HIV strains [59]. While virus strains have been identified that can
infect cells in the absence of CD4 (reviewed in [60]), none have
been identified that can infect cells in the absence of a suitable
coreceptor. In addition, virus strains that can use coreceptors other
than CCR5 or CXCR4 to infect primary human cells are
exceedingly rare. However, targeting CXCR4 alone could provide
a selective advantage to CCR5-tropic virus strains. Suppression of
CXCR4 by plerixafor in vitro can lead to the emergence of CCR5-
tropic virus strains [61], and highly active antiretroviral therapy
can sometimes result in enhanced prevalence of R5 relative to R5/
X4 virus strains in infected patients [62]. In the humanized mouse
model under the conditions studied here, partial loss of cxcr4 in
human T cells due to treatment with X4-ZFNs provided selective
pressure for either the evolution or emergence of a pre-existing
single amino acid mutation in the V3 loop of the infecting X4
HIV-1 strain that enabled it to use CCR5 as efficiently as
CXCR4. Thus, just as either genetic or therapeutic suppression of
CCR5 can provide an advantage to virus strains that use CXCR4,
deletion of CXCR4 is expected to provide an advantage to CCR5-
tropic viruses. However, this could provide a clinical benefit given
the increased in vitro pathogenicity and correlation with progres-
sion to AIDS of X4-tropic HIV.
While humanized mouse models provided a logical first
approach to examine in vivo efficacy of CXCR4 disruption, this
system does not make it possible to fully assess the functional
impact of CXCR4 loss on CD4+ T cell function. To study this in
the most rigorous way possible, we have explored the possibility of
targeting CCR5 and CXCR4 in CD4+ T cells derived from rhesus
macaques. Following re-design of the R5-ZFNs to account for
sequence differences between the human and macaque alleles, we
found that ZFNs could disrupt both alleles with reasonable
efficiency in macaque CD4+ T cells. By inactivating CXCR4
singly and in combination with CCR5, it will be possible to study
the effects of CXCR4 loss on T cell function as well as virus
infection in a more relevant animal model.
Supporting Information
Figure S1 The DNA binding preference of the X4-ZFP left and
X4-ZFP right was determined empirically by systemic evolution of
ligands by exponentialenrichment(SELEX). Briefly,a random pool
of oligonucleotides was mixed with each ZFP. Unbound oligos were
washed and bound oligos were amplified. After four rounds of
selection, the enriched oligo pool was sequenced, and a position
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PLoS Pathogens | www.plospathogens.org 13 April 2011 | Volume 7 | Issue 4 | e1002020weighted matrix was generated for the 12 bp target site and one
flanking residue per side (faded). Nucleotides corresponding to the
wild type cxcr4 sequence are shown above the horizontal line.
(TIF)
Figure S2 Treatment with X4-ZFNs prevents CD4 downregu-
lation by HIV-1. CD4 is profoundly downregulated on live CD3+
cells HIV-1 infected cultures that were NTD or treated with R5-
ZFNs but not X4-ZFNs. Thus, the limited cell growth remaining
by 19 days post infection in NTD cultures and those treated with
R5-ZFNs is due to HIV-1 induced CD4 downregulation, and thus
the protective effect on cell growth for CD3+CD4+ cells is
underestimated by the growth curves in Figure 4A. Cells are from
same experiment as Figure 4.
(TIF)
Table S1 Deep sequencing results of cxcr4 disruptions.
(XLS)
Table S2 Putative off-target sites of X4-ZFNs.
(XLS)
Table S3 Surveyor nuclease data after treatment with X4-ZFNs
and challenge by HIV-1.
(XLS)
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